Trial Master File deficiencies remain a recurring area of concern during regulatory inspections. Missing documents, incomplete audit trails and records filed too late can make it difficult to reconstruct how a clinical trial was managed, even when the study itself was conducted correctly.
For a CRO, choosing the wrong eTMF software can cause more than an administrative inconvenience. It can lead to costly setup, slow team adoption, fragmented oversight, and increased compliance risk. The right solution should help study teams maintain a complete, current, and inspection-ready TMF throughout the trial, not just prepare documentation shortly before an audit.
What is an eTMF and why has it become essential?
An electronic Trial Master File, or eTMF, is a digital system used to collect, organise, review, approve and archive the essential records generated during a clinical trial. Under ICH E6(R3) Good Clinical Practice, essential records are the documents, data, and relevant metadata that support trial management and enable evaluation of trial conduct and the reliability of its results.
The eTMF therefore provides the documented history of the study: what happened, when it happened, who was responsible and which evidence supports each decision.
Paper, hybrid and fully electronic TMFs
A paper TMF relies on physical binders and manual filing. Access is limited by location, version control is difficult, and remote review requires scanning or physical transfer of documents.
A hybrid TMF combines paper and electronic records. While it supports a gradual transition, it may create uncertainty about which repository holds the authoritative version of each document. A fully electronic TMF centralises records and metadata in controlled environment. Its main advantages include:
- secure remote access for authorised users.
- Controlled document versions.
- Traceable review and approval workflows.
- Automatic audit trails.
- Faster document retrieval.
- Continuous completeness and quality monitoring.
- More efficient support for remote inspections.
The EMA guideline on the content, management and archiving of the clinical Trial Master File states that an electronic TMF should provide adequate security and reliability and protect documents from loss, alteration or corruption. Technology alone does not make a TMF inspection-ready. The platform must support clearly defined processes, responsibilities, quality controls, and filing timelines.
Request more info to explore ACTide eTMF:
Five key criteria for choosing eTMF software for clinical trials
The best eTMF platform is not necessarily the one with the longest feature list. It is the solution that best matches the study model, regulatory scope, and operational needs of the CRO and sponsors. Use a clear set of criteria to guide the evaluation.
Regulatory compliance and system validation
An eTMF must support the integrity, authenticity and traceability of electronic records.
For studies under FDA jurisdiction, assess how the platform supports applicable 21 CFR Part 11 requirements for electronic records and electronic signatures.
For European trials, the assessment should consider:
- ICH GCP requirements.
- Regulation (EU) No 536/2014.
- EMA guidance on computerised systems.
- GDPR and data-protection obligations.
- Applicable GxP requirements based on the system’s intended use.
Regulation (EU) No 536/2014 requires sponsors and investigators to maintain a TMF that is readily available and directly accessible to authorities upon request.
Ask the vendor for documented evidence covering validation, audit trails, access controls, electronic signatures, backup, recovery and change management. Assess Annex 11 where its GMP computerised-system requirements are relevant to the intended GxP use; do not treat it as a generic substitute for clinical-trial regulations.
Integration with the eCRF and other eClinical systems
Disconnected systems create duplicate work. Documents may need manual export, renaming, classification, and upload, increasing the risk of delays or filing errors.
An eTMF integrated with electronic data capture and eCRF systems can reduce fragmentation between trial documentation and clinical data management. Integration should be assessed at the process level, not just as a technical check. Ask which events generate documents, how metadata is transferred, and whether the integration preserves the original record, its context, and audit trail. The EMA guideline on computerised systems and electronic data in clinical trials reinforces the importance of validation, traceability, security, and controlled data transfers across electronic systems.tems.
Ease of configuration and onboarding
A feature-rich platform offers limited value if every study requires lengthy custom development or extensive training. For CROs managing multiple protocols and sponsors, the eTMF should support:
- reusable study templates.
- Configurable document structures.
- Defined approval workflows.
- Placeholders and expected-document lists.
- Automated reminders.
- Straightforward user onboarding.
- Study-specific configuration without unnecessary development.
During a demo, ask the vendor to configure a realistic study scenario. This provides more useful evidence than a generic feature presentation.
Ask your free demo today:
Granular roles and permissions
Sponsors, CRO teams, investigators, monitors, and external partners should not all have the same level of access.
The platform should provide granular, profile-based permissions covering:
- document viewing.
- Uploading and editing.
- Quality control.
- Review and approval.
- Study, country and site access.
- Administrative functions.
- Report generation.
Permission changes should be documented in the audit trail. This supports confidentiality, accountability, and sponsor oversight, areas highlighted in regulatory discussions on data integrity and electronic systems in clinical research.
Inspection readiness and real-time TMF oversight
Inspection readiness is a continuous state, not a one-time clean-up activity.
The eTMF should give teams real-time visibility over:
- missing and overdue documents.
- Documents awaiting review or approval.
- Filing timeliness.
- Quality-control status.
- Completeness by study, country and site.
- Expired or superseded records.
- User and document activity.
The system should make records easy to search, retrieve, and export without disrupting normal trial operations.
Red flags to avoid in an eTMF platform
Some limitations may not appear until the study is underway. These warning signs should be investigated before signing. Incomplete or non-granular audit trail
A simple “last modified” date is not enough. The system should document who performed an action, what changed, when it changed, and, where required, why it changed.
The audit trail should be readable, searchable and available for inspection without relying on the software vendor to reconstruct it.
No effective integration with the EDC
If the eTMF and EDC operate as isolated repositories, teams may have to transfer documents and metadata manually. Ask whether the integration is native, configurable, or dependent on custom projects and third-party connectors.
A rigid document structure
The platform should support the organisation’s reference model and study-specific requirements. A structure that cannot adapt may force the team to change valid operational processes just to fit the software.
The TMF Reference Model provides an industry-supported framework for harmonising TMF content and terminology. It is not a regulation, but it can reduce variability and make collaboration between sponsors, CROs and vendors more efficient.
No documented regulatory experience
A vendor should be able to explain how the system is validated, how changes are controlled and what documentation is provided to customers.
Be cautious if answers remain generic or if the vendor cannot provide evidence of:
- a defined software development lifecycle.
- Validation documentation.
- Release and change-control procedures.
- Security and business-continuity measures.
- Regulatory domain expertise.
- Audit and inspection support.
Request your demo to see how the ACTide eTMF:
Questions to ask an eTMF vendor before signing
A structured vendor assessment should prioritize software functionality, then the operating model behind it.
Ask these questions before making a decision:
- How does the system support 21 CFR Part 11, ICH GCP and the EU Clinical Trials Regulation?
- Is the platform validated for its intended use, and which validation documents will we receive?
- Where applicable, how are Annex 11 expectations addressed?
- How long does it take to configure and launch a new study?
- Can our team configure structures and workflows independently?
- Can the TMF structure follow the current DIA/CDISC TMF Reference Model or an alternative model?
- How does the eTMF integrate with the EDC and other clinical systems?
- How are document migrations and metadata reconciliations managed?
- Which real-time metrics are available for completeness, quality and timeliness?
- How do you support remote regulatory inspections?
- What happens to our records and audit trails at contract termination?
- How are releases, security updates and system changes validated and communicated?
European requirements and implementation practices continue to evolve. CROs operating across multiple countries should also monitor guidance from the Heads of Medicines Agencies Clinical Trials Coordination Group.
What ACTide eTMF concretely offers
ACTide eTMF is available as a stand-alone solution or as an integrated component of ACTide eCRF. It is designed to help CROs, sponsors and sites manage study documentation in centralized, controlled environment.
Its documented capabilities include native support for the DIA TMF Reference Model, configurable alternative reference models, complete document audit trail, granular profile-based access, document version and release management, placeholders for expected documents, default and configurable approval workflows, automated reminders, document-status tracking, standard and customised reports, automatic quality checks for missing documents and sign-offs, integrated viewing of common file formats, direct storage of TMF-related emails, automatic backups, quarantine protection for uploaded files, and real-time document access for sponsors, CROs, countries, and sites.
As part of the wider ACTide eClinical ecosystem, the module can connect trial documentation with clinical data capture and related study processes. This gives CROs the flexibility to adopt eTMF as a focused service or within a broader, integrated environment.
The most useful evaluation is based on your own protocol, reference model, roles and approval processes.
Request your demo to see how the eTMF can be configured around a real study scenario.